Regeneron’s (REGN) odronextamab was granted FDA orphan designation as a treatment of splenic marginal zone lymphoma, according to a post to the ...

In the marginal zone lymphoma trial, 70% of patients had a complete response and 91% had an overall response. As this trial is still ongoing, Lossos is presenting interim results at the conference ...

IOR - Institute of Oncology Research, Bellinzona, Switzerland.

Revlimid’s approval in this setting was based on the AUGMENT trial, which included patients with follicular lymphoma as well as another type of NHK known as marginal zone lymphoma. That showed a ...

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

The pairing of Revlimid (lenalidomide) and Rituxan (rituximab) – known as the R 2 regimen – has been cleared for patients with previously-treated follicular lymphoma (FL) and marginal zone ...

Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. They help your body fight infections. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the ...

ClinicalTrials.gov was searched from database inception to May 20, 2024, for phase 3 RCTs of indolent lymphomas, including follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukaemia or ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...